<p>矿物疗法公司（Mineralys Therapeutics, Inc.）（NASDAQ:MLYS - 获取免费报告）的股票在覆盖该股票的七家研究公司中获得了 “适度买入” 的共识评级，MarketBeat Ratings 报告称。一位研究分析师对该股票给予了卖出建议，一位给予了持有建议，五位给予了买入建议。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价为 46.6667 美元。</p>
<p>获取 <strong>Mineralys Therapeutics</strong> 的提醒：</p>
<ul>
<li>关于 Mineralys 情人节首次公开募股，有很多值得期待的地方</li>
</ul>
<p>几位分析师最近对 MLYS 股票进行了评论。富国银行（Wells Fargo &amp; Company）在 11 月 11 日的研究报告中将 Mineralys Therapeutics 的目标价从 50.00 美元上调至 55.00 美元，并给予该公司 “超配” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Mineralys Therapeutics 的 “卖出（d-）” 评级。高盛集团（Goldman Sachs Group）在 9 月 9 日的研究报告中将 Mineralys Therapeutics 的目标价从 32.00 美元上调至 52.00 美元，并给予该公司 “买入” 评级。美国银行（Bank of America）在 8 月 28 日的报告中将 Mineralys Therapeutics 的目标价从 38.00 美元上调至 43.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在 11 月 12 日的报告中将 Mineralys Therapeutics 的目标价从 52.00 美元上调至 56.00 美元，并给予该公司 “买入” 评级。</p>
<p><strong>查看我们对 Mineralys Therapeutics 的最新分析</strong></p>
<h2>Mineralys Therapeutics 的内部买卖</h2>
<p>在相关消息中，董事亚历山大·M·戈德（Alexander M. Gold）在 11 月 11 日的交易中出售了 15,000 股该公司的股票。股票以平均价格 43.98 美元出售，总价值为 659,700.00 美元。该交易在向 SEC 的法律文件中披露，相关文件可在此链接查看。此外，首席执行官乔恩·康格尔顿（Jon Congleton）在 11 月 11 日的交易中出售了 200,000 股 Mineralys Therapeutics 的股票。该股票以平均价格 45.44 美元出售，总交易额为 9,088,000.00 美元。交易完成后，首席执行官直接持有该公司 631,305 股股票，价值约为 28,686,499.20 美元。此交易代表其持股比例下降了 24.06%。有关此交易的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士已出售了价值 62,019,643 美元的 1,416,793 股公司股票。公司内部人士持有 25.56% 的股票。</p>
<h2>Mineralys Therapeutics 的机构交易</h2>
<p>几家大型投资者最近调整了对 MLYS 的持股。威灵顿管理集团（Wellington Management Group LLP）在第一季度将其在 Mineralys Therapeutics 的股份增加了 32.8%。威灵顿管理集团现在拥有 121,557 股该公司的股票，价值 1,930,000 美元，此前在上个季度增持了 30,028 股。Geode Capital Management LLC 在第二季度将其在 Mineralys Therapeutics 的持股增加了 19.0%。Geode Capital Management LLC 现在拥有 954,560 股该公司的股票，价值 12,917,000 美元，此前在上个季度购买了 152,560 股。Voya Investment Management LLC 在第一季度购买了 Mineralys Therapeutics 的新股份，价值约为 255,000 美元。Strs Ohio 在第一季度购买了 Mineralys Therapeutics 的新股份，价值约为 359,000 美元。最后，高盛集团（Goldman Sachs Group Inc.）在第一季度将其在 Mineralys Therapeutics 的持股增加了 166.6%。高盛集团现在拥有 298,395 股该公司的股票，价值 4,739,000 美元，此前在上个季度增持了 186,480 股。机构投资者持有该公司 84.46% 的股票。</p>
<h2>Mineralys Therapeutics 股票下跌 1.1%</h2>
<p>Mineralys Therapeutics 的股票在周五开盘价为 38.50 美元。Mineralys Therapeutics 的十二个月最低价为 8.24 美元，最高价为 47.65 美元。该公司的市值为 30.5 亿美元，市盈率为-13.05，贝塔值为 0.40。该股票的 50 日移动平均线为 41.24 美元，200 日移动平均线为 26.74 美元。</p>
<p>Mineralys Therapeutics（NASDAQ:MLYS - 获取免费报告）在 11 月 10 日最后发布了其财报。该公司报告本季度每股收益（EPS）为-0.52 美元，超过了共识预期的-0.66 美元，超出幅度为 0.14 美元。整体来看，股票分析师预计 Mineralys Therapeutics 在本年度将发布-4.23 美元的每股收益。</p>
<h2>Mineralys Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Mineralys Therapeutics, Inc.是一家临床阶段的生物制药公司，开发用于治疗高血压和慢性肾病的疗法。其临床阶段的产品候选药物是 lorundrostat，一种专有的口服给药、高选择性的醛固酮合成酶抑制剂，用于治疗受异常升高的醛固酮影响的心肾疾病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Mineralys Therapeutics</li>
<li>3 个股票代码引领了迷因股的复兴</li>
<li>火箭实验室的大反弹？分析师认为此次下跌是个机会</li>
<li>经济报告在成功投资策略中的作用</li>
<li>Meta 的人工智能时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>成长股：它们是什么，它们又不是些什么</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUxZUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUxZUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Mineralys Therapeutics 吗？</h2>
<p>在你考虑 Mineralys Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们在更广泛的市场注意到之前就买入……而 Mineralys Therapeutics 并不在名单上。</p>
<p>虽然 Mineralys Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MLYS

<p>Mineralys Therapeutics, Inc.（纳斯达克代码：MLYS）获得了七家研究公司的 “适度买入” 共识评级。分析师设定的 12 个月平均目标价格为 46.67 美元。最近的内部交易包括首席执行官和一名董事的重大股票出售。机构投资者持有该公司 84.46% 的股份。该股票开盘价为 38.50 美元，市值为 30.5 亿美元。Mineralys 报告的季度每股收益为（0.52 美元），超出预期。该公司开发用于治疗高血压和慢性肾病的疗法</p>

<p>Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) have been given a consensus rating of &#34;Moderate Buy&#34; by the seven research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $46.6667.</p>
<div class="lb-trans"><p>矿物疗法公司（Mineralys Therapeutics, Inc.）（NASDAQ:MLYS - 获取免费报告）的股票在覆盖该股票的七家研究公司中获得了 “适度买入” 的共识评级，MarketBeat Ratings 报告称。一位研究分析师对该股票给予了卖出建议，一位给予了持有建议，五位给予了买入建议。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价为 46.6667 美元。</p>
</div><p>Get <strong>Mineralys Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Mineralys Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>There's a Lot to Love About Mineralys' Valentine's Day IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>关于 Mineralys 情人节首次公开募股，有很多值得期待的地方</li>
</ul>
</div><p>Several analysts recently commented on MLYS shares. Wells Fargo &amp; Company increased their price objective on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. The Goldman Sachs Group upped their price objective on Mineralys Therapeutics from $32.00 to $52.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, September 9th. Bank of America lifted their target price on Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, August 28th. Finally, HC Wainwright upped their price target on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 12th.</p>
<div class="lb-trans"><p>几位分析师最近对 MLYS 股票进行了评论。富国银行（Wells Fargo &amp; Company）在 11 月 11 日的研究报告中将 Mineralys Therapeutics 的目标价从 50.00 美元上调至 55.00 美元，并给予该公司 “超配” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Mineralys Therapeutics 的 “卖出（d-）” 评级。高盛集团（Goldman Sachs Group）在 9 月 9 日的研究报告中将 Mineralys Therapeutics 的目标价从 32.00 美元上调至 52.00 美元，并给予该公司 “买入” 评级。美国银行（Bank of America）在 8 月 28 日的报告中将 Mineralys Therapeutics 的目标价从 38.00 美元上调至 43.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在 11 月 12 日的报告中将 Mineralys Therapeutics 的目标价从 52.00 美元上调至 56.00 美元，并给予该公司 “买入” 评级。</p>
</div><p><strong>View Our Latest Analysis on Mineralys Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Mineralys Therapeutics 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Mineralys Therapeutics</h2>
<div class="lb-trans"><h2>Mineralys Therapeutics 的内部买卖</h2>
</div><p>In related news, Director Alexander M. Gold sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $43.98, for a total value of $659,700.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jon Congleton sold 200,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $45.44, for a total transaction of $9,088,000.00. Following the completion of the sale, the chief executive officer directly owned 631,305 shares of the company's stock, valued at approximately $28,686,499.20. This trade represents a 24.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,416,793 shares of company stock worth $62,019,643. 25.56% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事亚历山大·M·戈德（Alexander M. Gold）在 11 月 11 日的交易中出售了 15,000 股该公司的股票。股票以平均价格 43.98 美元出售，总价值为 659,700.00 美元。该交易在向 SEC 的法律文件中披露，相关文件可在此链接查看。此外，首席执行官乔恩·康格尔顿（Jon Congleton）在 11 月 11 日的交易中出售了 200,000 股 Mineralys Therapeutics 的股票。该股票以平均价格 45.44 美元出售，总交易额为 9,088,000.00 美元。交易完成后，首席执行官直接持有该公司 631,305 股股票，价值约为 28,686,499.20 美元。此交易代表其持股比例下降了 24.06%。有关此交易的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士已出售了价值 62,019,643 美元的 1,416,793 股公司股票。公司内部人士持有 25.56% 的股票。</p>
</div><h2>Institutional Trading of Mineralys Therapeutics</h2>
<div class="lb-trans"><h2>Mineralys Therapeutics 的机构交易</h2>
</div><p>Several large investors have recently modified their holdings of MLYS. Wellington Management Group LLP grew its stake in Mineralys Therapeutics by 32.8% during the first quarter. Wellington Management Group LLP now owns 121,557 shares of the company's stock valued at $1,930,000 after acquiring an additional 30,028 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Mineralys Therapeutics by 19.0% during the second quarter. Geode Capital Management LLC now owns 954,560 shares of the company's stock valued at $12,917,000 after purchasing an additional 152,560 shares in the last quarter. Voya Investment Management LLC bought a new stake in shares of Mineralys Therapeutics in the first quarter worth about $255,000. Strs Ohio purchased a new stake in shares of Mineralys Therapeutics in the first quarter worth about $359,000. Finally, Goldman Sachs Group Inc. boosted its stake in Mineralys Therapeutics by 166.6% during the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company's stock valued at $4,739,000 after buying an additional 186,480 shares during the last quarter. Institutional investors own 84.46% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对 MLYS 的持股。威灵顿管理集团（Wellington Management Group LLP）在第一季度将其在 Mineralys Therapeutics 的股份增加了 32.8%。威灵顿管理集团现在拥有 121,557 股该公司的股票，价值 1,930,000 美元，此前在上个季度增持了 30,028 股。Geode Capital Management LLC 在第二季度将其在 Mineralys Therapeutics 的持股增加了 19.0%。Geode Capital Management LLC 现在拥有 954,560 股该公司的股票，价值 12,917,000 美元，此前在上个季度购买了 152,560 股。Voya Investment Management LLC 在第一季度购买了 Mineralys Therapeutics 的新股份，价值约为 255,000 美元。Strs Ohio 在第一季度购买了 Mineralys Therapeutics 的新股份，价值约为 359,000 美元。最后，高盛集团（Goldman Sachs Group Inc.）在第一季度将其在 Mineralys Therapeutics 的持股增加了 166.6%。高盛集团现在拥有 298,395 股该公司的股票，价值 4,739,000 美元，此前在上个季度增持了 186,480 股。机构投资者持有该公司 84.46% 的股票。</p>
</div><h2>Mineralys Therapeutics Stock Down 1.1%</h2>
<div class="lb-trans"><h2>Mineralys Therapeutics 股票下跌 1.1%</h2>
</div><p>Mineralys Therapeutics stock opened at $38.50 on Friday. Mineralys Therapeutics has a twelve month low of $8.24 and a twelve month high of $47.65. The company has a market capitalization of $3.05 billion, a P/E ratio of -13.05 and a beta of 0.40. The stock's 50 day moving average is $41.24 and its 200 day moving average is $26.74.</p>
<div class="lb-trans"><p>Mineralys Therapeutics 的股票在周五开盘价为 38.50 美元。Mineralys Therapeutics 的十二个月最低价为 8.24 美元，最高价为 47.65 美元。该公司的市值为 30.5 亿美元，市盈率为-13.05，贝塔值为 0.40。该股票的 50 日移动平均线为 41.24 美元，200 日移动平均线为 26.74 美元。</p>
</div><p>Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. As a group, equities analysts expect that Mineralys Therapeutics will post -4.23 EPS for the current year.</p>
<div class="lb-trans"><p>Mineralys Therapeutics（NASDAQ:MLYS - 获取免费报告）在 11 月 10 日最后发布了其财报。该公司报告本季度每股收益（EPS）为-0.52 美元，超过了共识预期的-0.66 美元，超出幅度为 0.14 美元。整体来看，股票分析师预计 Mineralys Therapeutics 在本年度将发布-4.23 美元的每股收益。</p>
</div><h2>Mineralys Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Mineralys Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.</p>
<div class="lb-trans"><p>Mineralys Therapeutics, Inc.是一家临床阶段的生物制药公司，开发用于治疗高血压和慢性肾病的疗法。其临床阶段的产品候选药物是 lorundrostat，一种专有的口服给药、高选择性的醛固酮合成酶抑制剂，用于治疗受异常升高的醛固酮影响的心肾疾病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Mineralys Therapeutics</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>Growth Stocks: What They Are, What They Are Not</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Mineralys Therapeutics</li>
<li>3 个股票代码引领了迷因股的复兴</li>
<li>火箭实验室的大反弹？分析师认为此次下跌是个机会</li>
<li>经济报告在成功投资策略中的作用</li>
<li>Meta 的人工智能时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>成长股：它们是什么，它们又不是些什么</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUxZUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MLYS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Mineralys Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Mineralys Therapeutics 吗？</h2>
</div><p>Before you consider Mineralys Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Mineralys Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们在更广泛的市场注意到之前就买入……而 Mineralys Therapeutics 并不在名单上。</p>
</div><p>While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Mineralys Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Mineralys Therapeutics, Inc.（纳斯达克股票代码：MLYS）获得分析师的平均评级为 “适度买入”